Abstract
Mitigation of failure modes in the continuous synthesis (CS) of a drug substance (DS) has the potential to widen the adoption of continuous manufacturing (CM) technologies by the pharmaceutical industry.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have